TECHNESCAN HIDA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECHNESCAN HIDA (TECHNESCAN HIDA).
Technetium Tc-99m mebrofenin is a radiopharmaceutical that, after intravenous administration, is taken up by hepatocytes via organic anion transporting polypeptides (OATPs) and excreted into the bile canaliculi via multidrug resistance-associated protein 2 (MRP2). It allows scintigraphic evaluation of hepatobiliary function by emitting gamma radiation detectable by a gamma camera.
| Metabolism | Not metabolized; excreted unchanged into bile via hepatobiliary transport. |
| Excretion | Primarily biliary excretion: 85-90% of administered dose is excreted into bile via the hepatobiliary system within 2 hours, with minimal renal elimination (<5%) and fecal excretion accounting for <2%. |
| Half-life | Terminal elimination half-life is approximately 1.5 hours (range 1-2 hours) in patients with normal hepatic function. In patients with hepatic impairment, half-life may be prolonged up to 4-6 hours. |
| Protein binding | Approximately 65-75% bound primarily to albumin and to a lesser extent to alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 0.4-0.6 L/kg, reflecting distribution primarily within the extracellular fluid space and hepatobiliary system. |
| Bioavailability | Only administered intravenously; bioavailability is 100% via IV route. |
| Onset of Action | After intravenous administration, hepatocyte uptake begins within minutes, with peak hepatic activity at 10-15 minutes post-injection. Biliary visualization occurs at 15-30 minutes. |
| Duration of Action | Duration of diagnostic imaging is approximately 60-90 minutes post-injection, with prompt clearance from the liver. Delayed transit may occur in cholestasis or hepatic dysfunction. |
5 mCi (185 MBq) administered intravenously as a single dose for hepatobiliary imaging.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required for renal impairment; excretion is primarily biliary. |
| Liver impairment | In severe hepatic impairment (Child-Pugh class C), consider reduction to 3 mCi (111 MBq) due to decreased hepatic extraction. |
| Pediatric use | 0.1 mCi/kg (3.7 MBq/kg) intravenously; minimum dose 0.5 mCi (18.5 MBq), maximum dose 5 mCi (185 MBq). |
| Geriatric use | No specific dose adjustment required; use standard adult dose (5 mCi) unless severe hepatic or renal dysfunction present. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECHNESCAN HIDA (TECHNESCAN HIDA).
| Breastfeeding | Tc-99m pertechnetate is excreted into breast milk with a milk-to-plasma ratio of approximately 2.2. After administration, breastfeeding should be interrupted for at least 4 days (multiple half-lives) to minimize radiation exposure to the infant. Prior to resumption, milk should be pumped and discarded. |
| Teratogenic Risk | Technetium-99m (Tc-99m) pertechnetate, the active component of TECHNESCAN HIDA, is a radioactive isotope. In pregnancy, radiation exposure poses risks of teratogenicity, particularly during organogenesis (weeks 2-8) and in the second trimester (weeks 8-15), with potential for fetal growth restriction, microcephaly, and increased cancer risk. First-trimester exposure carries highest risk for malformations. Use is contraindicated unless benefit clearly outweighs risk. |
■ FDA Black Box Warning
None
| Serious Effects |
History of hypersensitivity to mebrofenin or any component of the formulation.
| Precautions | Hypersensitivity reactions including anaphylaxis may occur. Ensure adequate hydration to minimize radiation exposure to the bladder. Use caution in patients with impaired hepatic function as lower hepatocyte uptake may reduce image quality. |
Loading safety data…
| Fetal Monitoring | In pregnant patients, perform a pregnancy test before administration. Monitor maternal vital signs during infusion. Fetal exposure should be estimated based on administered activity and gestational age; consider fetal dose assessment by a medical physicist. No specific fetal monitoring is typically required post-administration. |
| Fertility Effects | Tc-99m pertechnetate delivers gonadal radiation dose, which may impair fertility if cumulative exposure is high. Temporary reduction in spermatogenesis may occur in males. No direct evidence of permanent fertility impairment at diagnostic doses. |